Real‐world study on adoption of standard‐of‐care for transplant‐eligible newly diagnosed multiple myeloma patients between 2017 and 2020/2021 across France, Germany, Spain, and Italy-Reference-Cited by-同舟云学术

Real‐world study on adoption of standard‐of‐care for transplant‐eligible newly diagnosed multiple myeloma patients between 2017 and 2020/2021 across France, Germany, Spain, and Italy

Published:2022-07-12 Issue:4 Volume:109 Page:388-397
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:European J of Haematology

Author:

Weisel Katja¹,Wadlund Astrid Ottosson²,Gungor Guntug³,Dergarabetian Eileen⁴,Pacheco Cécile⁵,Masurkar Nihar⁵^ORCID,Rodriguez‐Otero Paula⁶

Affiliation:

1. Department of Oncology, Hematology, BMT with Section of Pneumology University Medical Center Hamburg‐Eppendorf Hamburg Germany

2. Janssen‐Cilag AB Solna Sweden

3. Janssen, Kavacık Beykoz/İstanbul Turkey

4. Janssen‐Cilag Limited Buckinghamshire UK

5. Cerner Enviza France SAS Paris France

6. Department of Hematology Clínica Universidad de Navarra Pamplona Navarra Spain

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13821

Reference23 articles.

1. Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’

2. International Agency for Research on Cancer and World Health Organization.Multiple myeloma Source: Globocan 2020. Accessed February 16 2022.https://gco.iarc.fr/today/data/factsheets/cancers/35‐Multiple‐myeloma‐fact‐sheet.pdf

Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy

4. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

5. Frontline therapy of multiple myeloma

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Response adaptive salvage treatment with daratumumab–lenalidomide–dexamethasone for newly diagnosed transplant‐eligible multiple myeloma patients failing front‐line bortezomib‐based induction therapy—ALLG MM21;British Journal of Haematology;2024-06-08

2. Real-world assessment of treatment multiple myeloma patients on the example of one hematology center;Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice;2023-10-19

3. Real‐world assessment of treatment patterns and outcomes in patients with relapsed‐refractory multiple myeloma in an Italian haematological tertiary care centre;British Journal of Haematology;2023-01-17